ONCOINVENT ASA (ONCIN.OL) Stock Price & Overview
OSL:ONCIN • NO0013711713
Current stock price
The current stock price of ONCIN.OL is 45.995 NOK. Today ONCIN.OL is up by 4.4%. In the past month the price increased by 8.48%.
ONCIN.OL Key Statistics
- Market Cap
- 206.058M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -48.72
- Dividend Yield
- N/A
ONCIN.OL Stock Performance
ONCIN.OL Stock Chart
ONCIN.OL Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ONCIN.OL.
ONCIN.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ONCIN.OL. ONCIN.OL has a great financial health rating, but its profitability evaluates not so good.
ONCIN.OL Earnings
ONCIN.OL Forecast & Estimates
9 analysts have analysed ONCIN.OL and the average price target is 49.98 NOK. This implies a price increase of 8.66% is expected in the next year compared to the current price of 45.995.
For the next year, analysts expect an EPS growth of 97.36% and a revenue growth 13900% for ONCIN.OL
ONCIN.OL Groups
Sector & Classification
ONCIN.OL Financial Highlights
Over the last trailing twelve months ONCIN.OL reported a non-GAAP Earnings per Share(EPS) of -48.72. The EPS increased by 70.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.55% | ||
| ROE | -207.87% | ||
| Debt/Equity | 0 |
ONCIN.OL Ownership
ONCIN.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.67 | 198.012B | ||
| SNW | SANOFI | 9.66 | 197.867B | ||
| 1SAN | SANOFI | 8.96 | 183.546B | ||
| UCB | UCB SA | 24.5 | 49.017B | ||
| UNC | UCB SA | 24.47 | 48.958B | ||
| MRK | MERCK KGAA | 12.71 | 45.674B | ||
| 1BAYN | BAYER AG-REG | 8.23 | 37.823B | ||
| BAYN | BAYER AG-REG | 8.17 | 37.587B | ||
| IPN | IPSEN | 12.93 | 13.217B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 17.05 | 10.222B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.102B | ||
| VIRP | VIRBAC SA | 16.21 | 2.928B | ||
| DMP | DERMAPHARM HOLDING SE | 16.85 | 2.283B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ONCIN.OL
Company Profile
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The firm is based in Bergen, Norway with a subsidiary in Oxford, UK.
Company Info
IPO: 2017-04-07
ONCOINVENT ASA
Gullhaugveien 7
Oslo OSLO NO
Employees: 36
Phone: 4722183305
ONCOINVENT ASA / ONCIN.OL FAQ
What does ONCOINVENT ASA do?
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The firm is based in Bergen, Norway with a subsidiary in Oxford, UK.
What is the stock price of ONCOINVENT ASA today?
The current stock price of ONCIN.OL is 45.995 NOK. The price increased by 4.4% in the last trading session.
What is the dividend status of ONCOINVENT ASA?
ONCIN.OL does not pay a dividend.
What is the ChartMill rating of ONCOINVENT ASA stock?
ONCIN.OL has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ONCOINVENT ASA (ONCIN.OL)?
ONCOINVENT ASA (ONCIN.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-48.72).
Can you provide the market cap for ONCOINVENT ASA?
ONCOINVENT ASA (ONCIN.OL) has a market capitalization of 206.06M NOK. This makes ONCIN.OL a Micro Cap stock.